| [1] |
Chiang GG, Abraham RT. Determination of the catalytic activities of mTOR and other members of the phosphoinositide-3-kinase-related kinase family [J]. Methods Mol Biol, 2004(281):125-141.
|
| [2] |
Zoncu R, Efeyan A, Sabatini DM. mTOR：from growth signal integration to cancer, diabetes and ageing [J]. Nat Rev Mol Cell Biol, 2011, 12(1):21-35.
|
| [3] |
Brown MC, Gromeier M. MNK inversely regulates TELO2 vs. DEPTOR to control mTORC1 signaling [J]. Mol Cell Oncol, 2017, 4(3):e1306010.
|
| [4] |
Liu P, Gan W, Chin YR, et al. PtdIns（3, 4, 5）P3-Dependent Activation of the mTORC2 Kinase Complex [J]. Cancer Discov, 2015, 5(11):1194-1209.
|
| [5] |
Laplante M, Sabatini DM. mTOR signaling in growth control and disease [J]. Cell, 2012, 149(2):274-293.
|
| [6] |
Nasr AB, Ponnala D, Sagurthi SR, et al. Molecular Docking studies of FKBP12-mTOR inhibitors using binding predictions [J]. Bioinformation, 2015, 11(6):307-315.
|
| [7] |
Schreiber KH, Ortiz D, Academia EC, et al. Rapamycin-mediated mTORC2 inhibition is determined by the relative expression of FK506-binding proteins [J]. Aging Cell, 2015, 14(2):265-273.
|
| [8] |
Khan KH, Yap TA, Yan L, et al. Targeting the PI3K-AKT-mTOR signaling network in cancer [J]. Chin J Cancer, 2013, 32(5):253-265.
|
| [9] |
Gowans GJ. Regulation and role of the LKB1-AMPK pathway [D]. Dundee：University of Dundee, 2014.
|
| [10] |
Jiang BH, Liu LZ. PI3K/PTEN signaling in angiogenesis and tumorigenesis [J]. Adv Cancer Res, 2009, 102(1):19-65.
|
| [11] |
Yuan TL, Cantley LC. PI3K pathway alterations in cancer：variations on a theme [J]. Oncogene, 2008, 27(41):5497-5510.
|
| [12] |
Foukas LC, Berenjeno IM, Gray A, et al. Activity of any class IA PI3K isoform can sustain cell proliferation and survival [J]. Proc Natl Acad Sci U S A, 2010, 107(25):11381-11386.
|
| [13] |
McGlade CJ, Ellis C, Reedijk M, et al. SH2 domains of the p85 alpha subunit of phosphatidylinositol 3-kinase regulate binding to growth factor receptors [J]. Mol Cell Biol, 1992, 12(3):991-997.
|
| [14] |
Balendran A, Casamayor A, Deak M, et al. PDK1 acquires PDK2 activity in the presence of a synthetic peptide derived from the carboxyl terminus of PRK2 [J]. Curr Biol, 1999, 9(8):393-404.
|
| [15] |
Leslie NR, Batty IH, Maccario H, et al. Understanding PTEN regulation：PIP2, polarity and protein stability [J]. Oncogene, 2008, 27(41):5464-5476.
|
| [16] |
Lin HP, Lin CY, Huo C, et al. Akt3 promotes prostate cancer proliferation cells through regulation of Akt, B-Raf, and TSC1/TSC2[J]. Oncotarget, 2015, 6(29):27097-27112.
|
| [17] |
Dibble CC, Elis W, Menon S, et al. TBC1D7 Is a third subunit of the TSC1-TSC2 complex upstream of mTORC1 [J]. Mol Cell, 2012, 47(4):535-546.
|
| [18] |
Yoshida S, Hong S, Suzuki T, et al. Redox regulates mammalian target of rapamycin complex 1（mTORC1）activity by modulating the TSC1/TSC2-Rheb GTPase pathway [J]. J Biol Chem, 2011, 286(37):32651-32660.
|
| [19] |
Mohan N, Shen Y, Dokmanovic M, et al. VPS34 regulates TSC1/TSC2 heterodimer to mediate RheB and mTORC1/S6K1 activation and cellular transformation [J]. Oncotarget, 2016, 7(32):52239-52254.
|
| [20] |
Han D, Li SJ, Zhu YT, et al. LKB1/AMPK/mTOR signaling pathway in non-small-cell lung cancer [J]. Asian Pac J Cancer Prev, 2013, 14(7):4033-4099.
|
| [21] |
Mirouse V, Swick LL, Kazgan N, et al. LKB1 and AMPK maintain epithelial cell polarity under energetic stress [J]. J Cell Biol, 2013, 203(2):387-392.
|
| [22] |
Hardie DG, Sakamoto K. AMPK：a key sensor of fuel and energy status in skeletal muscle [J]. Physiology（Bethesda）, 2006(21):48-60.
|
| [23] |
Green AS, Chapuis N, Lacombe C, et al. LKB1/AMPK/mTOR signaling pathway in hematological malignancies：from metabolism to cancer cell biology [J]. Cell Cycle, 2011, 10(13):2115-2120.
|
| [24] |
Wang W, Guan KL. AMP-activated protein kinase and cancer [J]. Acta Physiol（Oxf）, 2009, 196(1):55-63.
|
| [25] |
Dodd KM, Yang J, Shen MH, et al. mTORC1 drives HIF-1α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3 [J]. Oncogene, 2015, 34(17):2239-2250.
|
| [26] |
Jevtov I, Zacharogianni M, Oorschot MM, et al. TORC2 mediates the heat stress response in Drosophila by promoting the formation of stress granules [J]. J Cell Sci, 2015, 128(14):2497-2508.
|
| [27] |
Iadevaia V, Liu R, Proud CG. mTORC1 signaling controls multiple steps in ribosome biogenesis [J]. Semin Cell Dev Biol, 2014(36):113-120.
|
| [28] |
Yuan L, Sheng X, Willson AK, et al. Glutamine promotes ovarian cancer cell proliferation through the mTOR/S6 pathway [J]. Endocr Relat Cancer, 2015, 22(4):577-591.
|
| [29] |
Vikhreva PN, Shepelev MV, Korobko IV. mTOR-dependent transcriptional repression of Pdcd4 tumor suppressor in lung cancer cells [J]. Biochim Biophys Acta, 2014, 1839(1):43-49.
|
| [30] |
Csibi A, Lee G, Yoon SO, et al. The mTORC1/S6K1 pathway regulates glutamine metabolism through the eIF4B-dependent control of c-Myc translation [J]. Curr Biol, 2014, 24(19):2274-2280.
|
| [31] |
Dan HC, Antonia RJ, Baldwin AS. PI3K/Akt promotes feedforward mTORC2 activation through IKKα [J]. Oncotarget, 2016, 7(16):21064-21075.
|
| [32] |
Zinzalla V, Stracka D, Oppliger W, et al. Activation of mTORC2 by association with the ribosome [J]. Cell, 2011, 144(5):757.
|
| [33] |
Oh WJ, Wu CC, Kim SJ, et al. mTORC2 can associate with ribosomes to promote cotranslational phosphorylation and stability of nascent Akt polypeptide [J]. EMBO J, 2010, 29(23):3939-3951.
|
| [34] |
Renna M, Bento CF, Fleming A, et al. IGF-1 receptor antagonism inhibits autophagy [J]. Hum Mol Genet, 2013, 22(22):4528-4544.
|
| [35] |
Liu P, Gan W, Inuzuka H, et al. Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signaling to suppress tumorigenesis [J]. Nat Cell Biol, 2013, 15(11):1340-1350.
|
| [36] |
Masri J, Bernath A, Martin J, et al. mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor [J]. Cancer Res, 2007, 67(24):11712-11720.
|
| [37] |
Guertin DA, Sabatini DM. Defining the role of mTOR in cancer [J]. Cancer Cell, 2007, 12(1):9-22.
|
| [38] |
Cargnello M, Tcherkezian J, Roux PP. The expanding role of mTOR in cancer cell growth and proliferation [J]. Mutagenesis, 2015, 30(2):169-176.
|
| [39] |
Karthik GM, Ma R, Lövrot J, et al. mTOR inhibitors counteract tamoxifen-induced activation of breast cancer stem cells [J]. Cancer Lett, 2015, 367(1):76-87.
|
| [40] |
Caron A, Richard D, Laplante M. The Roles of mTOR Complexes in Lipid Metabolism [J]. Annu Rev Nutr, 2015(35):321-348.
|
| [41] |
Shor B, Gibbons JJ, Abraham RT, et al. Targeting mTOR globally in cancer：thinking beyond rapamycin [J]. Cell Cycle, 2009, 8(23):3831-3837.
|
| [42] |
Chatterjee A. Control of cell cycle progression by mTOR [D]. New York：City University of New York, 2015.
|
| [43] |
Teo T, Yu M, Yang Y, et al. Pharmacologic co-inhibition of Mnks and mTORC1 synergistically suppresses proliferation and perturbs cell cycle progression in blast crisis-chronic myeloid leukemia cells [J]. Cancer Lett, 2015, 357(2):612-623.
|
| [44] |
Feng L, Balakir R, Precht P, et al. Bcl-2 regulates chondrocyte morphology and aggrecan gene expression independent of caspase activation and full apoptosis [J]. J Cell Biochem, 2015, 74(4):576-586.
|
| [45] |
Zhou FF, Yan M, Guo GF, et al. Knockdown of eIF4E suppresses cell growth and migration, enhances chemosensitivity and correlates with increase in Bax/Bcl-2 ratio in triple-negative breast cancer cells [J]. Med Oncol, 2011, 28(4):1302-1307.
|
| [46] |
Harada H, Andersen JS, Mann M, et al. p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD [J]. Proc Natl Acad Sci U S A, 2001, 98(17):9666-9670.
|
| [47] |
Beuvink I, Boulay A, Fumagalli S, et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation [J]. Cell, 2005, 120(6):747-759.
|
| [48] |
Kenific CM, Debnath J. Cellular and metabolic functions for autophagy in cancer cells [J]. Trends Cell Biol, 2015, 25(1):37-45.
|
| [49] |
Jiang X, Overholtzer M, Thompson CB. Autophagy in cellular metabolism and cancer [J]. J Clin Invest, 2015, 125(1):47-54.
|
| [50] |
Chan EY. mTORC1 phosphorylates the ULK1-mAtg13-FIP200 autophagy regulatory complex [J]. Sci Signal, 2009, 2(84):pe51.
|
| [51] |
Jung CH, Ro SH, Cao J, et al. mTOR regulation of autophagy [J]. FEBS Lett, 2010, 584(7):1287-1295.
|
| [52] |
Easton JB, Houghton PJ. mTOR and cancer therapy [J]. Oncogene, 2006, 25(48):6436-6446.
|
| [53] |
Ortolani S, Ciccarese C, Cingarlini S, et al. Suppression of mTOR pathway in solid tumors：lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives [J]. Future Oncol, 2015, 11(12):1809-1828.
|
| [54] |
Sapienza PJ, Mauldin RV, Lee AL. Multi-timescale dynamics study of FKBP12 along the rapamycin-mTOR binding coordinate [J]. J Mol Biol, 2011, 405(2):378-394.
|
| [55] |
O'reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt [J]. Cancer Res, 2006, 66(3):1500-1508.
|
| [56] |
Vilar E, Perez-Garcia J, Tabernero J. Pushing the envelope in the mTOR pathway：the second generation of inhibitors [J]. Mol Cancer Ther, 2011, 10(3):395-403.
|
| [57] |
Neil J, Shannon C, Mohan A, et al. ATP-site binding inhibitor effectively targets mTORC1 and mTORC2 complexes in glioblastoma [J]. International Journal of Oncology, 2016, 48(3):1045-1052.
|
| [58] |
Ma BB, Lui VW, Hui CW, et al. Preclinical evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal cancer models [J]. Cancer Lett, 2014, 343(1):24-32.
|
| [59] |
Gupta M, Hendrickson AE, Yun SS, et al. Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies [J]. Blood, 2012, 119(2):476-487.
|
| [60] |
Wu S, Wang S, Zheng S, et al. MSK1-mediated β-catenin phosphorylation confers resistance to PI3K/mTOR inhibitors in glioblastoma[J]. Mol Cancer Ther, 2016, 15(7):1656-1668.
|
| [61] |
Elkabets M, Pazarentzos E, Juric D, et al. AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas [J]. Cancer Cell, 2015, 27(4):533-546.
|
| [62] |
Li T, Yang Y, Li X, et al. EGFR- and AKT-mediated reduction in PTEN expression contributes to tyrphostin resistance and is reversed by mTOR inhibition in endometrial cancer cells [J]. Mol Cell Biochem, 2012, 361(1-2):19-29.
|
| [63] |
Odaka Y, Xu B, Luo Y, et al. Dihydroartemisinin inhibits the mammalian target of rapamycin-mediated signaling pathways in tumor cells [J]. Carcinogenesis, 2014, 35(1):192-200.
|
| [64] |
Zhou H, Shang C, Wang M, et al. Ciclopirox olamine inhibits mTORC1 signaling by activation of AMPK [J]. Biochem Pharmacol, 2016(116):39-50.
|
| [65] |
Chen W, Luo Y, Liu L, et al. Cryptotanshinone inhibits cancer cell proliferation by suppressing mTOR-mediated cyclin D1 expression and Rb phosphorylation [J]. Cancer Prev Res（Phila）, 2010, 3(8):1015-1025.
|
| [66] |
Beevers CS, Li F, Liu L, et al. Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells [J]. Int J Cancer, 2006, 119(4):757-764.
|